Sanofi Pasteur MSD applies to update marketing license for Gardasil |
|
|
|
Published
:
Wed, 25 Apr 2007 08:35
|
LONDON (Thomson Financial) - Sanofi Pasteur MSD has applied to extend the marketing license for its cervical cancer vaccine Gardasil in Europe, following a similar move in the US last week.The company, a joint venture between Sanofi Aventis and Merck & Co, has submitted cross-protection data showing the jab protects against additional virus types not present in the vaccine, which cause more than 10 pct of cervical cancers.The virus-types also caused around 25-40 pct of pre-cancerous and potentially pre-cancerous lesions.Gardasil has been proven to provide 100 pct protection against types 6, 11, 16 and 18 of the human papillomavirus, a sexually transmitted infection which cause 75 pct of all cervical cancers.amy.brown@thomson.comab/tcCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
Print this Story
Sanofi-Pasteur wins US FDA licence for 1st avian flu vaccine for humans 